# Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL

> **NCT06890585** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Li Zhiming** · enrollment: 128 (estimated)

## Conditions studied

- BTK Inhibitors
- Histone Deacetylase Inhibitor
- Double Express Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** ZCR-CHOP
- **DRUG:** R-CHOP

## Key facts

- **NCT ID:** NCT06890585
- **Lead sponsor:** Li Zhiming
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2025-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06890585

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06890585, "Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06890585. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*